Ziopharm Oncology Inc. (ZIOP) Lowered to “Hold” at Zacks Investment Research
Ziopharm Oncology Inc. (NASDAQ:ZIOP) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday.
According to Zacks, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. “
Other research analysts have also recently issued reports about the stock. Griffin Securities reissued a “buy” rating and set a $21.00 price objective on shares of Ziopharm Oncology in a report on Friday, July 1st. Mizuho reissued a “neutral” rating and set a $5.00 price objective (down from $7.00) on shares of Ziopharm Oncology in a report on Monday, July 18th. Finally, Wells Fargo & Co. reissued an “underperform” rating on shares of Ziopharm Oncology in a report on Friday, July 15th. Five equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Ziopharm Oncology presently has an average rating of “Hold” and a consensus target price of $9.75.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/ziopharm-oncology-inc-ziop-lowered-to-hold-at-zacks-investment-research.html
Ziopharm Oncology (NASDAQ:ZIOP) traded down 0.74% during mid-day trading on Wednesday, reaching $5.38. 436,650 shares of the company’s stock traded hands. Ziopharm Oncology has a 12-month low of $4.45 and a 12-month high of $14.93. The stock has a 50 day moving average of $5.45 and a 200 day moving average of $6.30. The company’s market cap is $702.07 million.
Ziopharm Oncology (NASDAQ:ZIOP) last released its quarterly earnings data on Tuesday, August 9th. The biotechnology company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.90. Ziopharm Oncology had a negative net margin of 2,292.26% and a negative return on equity of 100.01%. The company had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $1.52 million. During the same period in the previous year, the firm earned ($0.11) earnings per share. The firm’s revenue for the quarter was up 525.0% on a year-over-year basis. On average, equities research analysts predict that Ziopharm Oncology will post ($1.34) earnings per share for the current fiscal year.
Institutional investors have recently bought and sold shares of the company. Advisor Group Inc. purchased a new position in Ziopharm Oncology during the second quarter worth $105,000. Royal Bank of Canada raised its position in Ziopharm Oncology by 18.8% in the second quarter. Royal Bank of Canada now owns 19,235 shares of the biotechnology company’s stock worth $105,000 after buying an additional 3,046 shares during the last quarter. Oppenheimer & Co. Inc. raised its position in Ziopharm Oncology by 4.8% in the second quarter. Oppenheimer & Co. Inc. now owns 20,100 shares of the biotechnology company’s stock worth $110,000 after buying an additional 919 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in Ziopharm Oncology during the second quarter worth $114,000. Finally, Principal Financial Group Inc. raised its position in Ziopharm Oncology by 5.5% in the second quarter. Principal Financial Group Inc. now owns 21,388 shares of the biotechnology company’s stock worth $117,000 after buying an additional 1,124 shares during the last quarter. Institutional investors and hedge funds own 44.94% of the company’s stock.
About Ziopharm Oncology
ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ziopharm Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ziopharm Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.